<div id="readability-page-1"><div>(Alliance News) - AstraZeneca PLC on Monday said Imfinzi, in combination with chemotherapy, has been recommended for approval in the EU for the treatment of adult patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers.The Committee for Medicinal Products for Human Use of the European Medicines Agency based its positive opinion on event-free survival and overall survival data from the Matterhorn phase three trial, AstraZeneca said. The trial showed a 29% reduction in the risk of progression, recurrence or death and a 22% reduction in the risk of death for the Imfinzi regimen versus chemotherapy alone.&#34;The CHMP recommendation marks further progress toward our goal to offer novel approaches in early-stage cancers where there is the greatest chance for cure and brings us closer to providing the third perioperative Imfinzi-based regimen in the EU,&#34; said Susan Galbraith, executive vice president for Oncology Haematology R&amp;D at AstraZeneca. Imfinzi is approved in the US and other countries in the same indication based on the Matterhorn results. Regulatory applications are currently under review in Japan and other countries.In addition, the FTSE 100 listing said trading in its shares will begin on the New York Stock Exchange on Monday for the first time. AstraZeneca said the trading of its shares is now aligned across the NYSE, the London Stock Exchange and Nasdaq Stockholm under a harmonised listing structure. &#34;This will allow even more investors to participate in AstraZeneca's future,&#34; commented Chair Michel Demare. Last July, AstraZeneca pledged to invest USD50 billion in the US for medicines manufacturing and research &amp; development. In October, the Cambridge, England-based pharmaceuticals company struck a deal with the US government adopting a most-favoured-nation drug pricing model, designed to lower US costs to match the lowest in developed nations.AstraZeneca also reached an agreement with the US Department of Commerce to delay Section 232 tariffs for three years, enabling it to fully onshore medicines manufacturing so that all of its medicines sold in the US are made in the US. Shares in AstraZeneca were up 1.2% at 13,758.00 pence each in London on Monday morning. The wider FTSE 100 index was down 0.3%.By Jeremy Cutler, Alliance News reporterComments and questions to newsroom@alliancenews.comCopyright 2026 Alliance News Ltd. All Rights Reserved.</div></div>

阿斯利康获得了欧盟对其药物 Imfinzi 的积极推荐，该药物与化疗联合用于治疗早期胃癌。该推荐基于显著的试验结果，显示出降低了疾病进展和死亡的风险。此外，阿斯利康的股票将在纽约证券交易所上市，统一其在主要交易所的上市。该公司承诺在美国制造和研发方面投资 500 亿美元，并已达成协议以降低药物成本和推迟关税，从而增强其在美国的运营能力

AstraZeneca hails Imfinzi green light ahead of New York trading debut

marketscreener

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

医疗业 ETF - SPDR

阿斯利康

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

基因改革 ETF - ARK

美国制药 ETF - iShares

医疗业 ETF - Vanguard

标普全球医疗股指数 ETF - iShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

AstraZeneca PLC ADRhedged

2 倍做多纳斯达克生物技术 ETF - ProShares

阿斯利康在纽约交易首次亮相前对 Imfinzi 获得批准表示欢迎